Cytokinetics, Incorporated (NASDAQ:CYTK) has been given an average recommendation of “Buy” by the fourteen ratings firms that are presently covering the firm, MarketBeat.com reports. Three investment analysts have rated the stock with a hold recommendation, ten have given a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $22.13.

CYTK has been the subject of a number of research analyst reports. Zacks Investment Research cut Cytokinetics, from a “hold” rating to a “strong sell” rating in a report on Thursday, May 4th. HC Wainwright set a $26.00 price target on Cytokinetics, and gave the company a “buy” rating in a report on Thursday, August 3rd. ValuEngine raised Cytokinetics, from a “sell” rating to a “hold” rating in a report on Friday, June 2nd. BidaskClub raised Cytokinetics, from a “sell” rating to a “hold” rating in a report on Thursday, July 13th. Finally, Cowen and Company reaffirmed a “buy” rating and issued a $19.00 price target on shares of Cytokinetics, in a report on Friday, August 4th.

TRADEMARK VIOLATION WARNING: “Cytokinetics, Incorporated (CYTK) Given Average Recommendation of “Buy” by Analysts” was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this report on another domain, it was copied illegally and republished in violation of United States and international copyright and trademark laws. The correct version of this report can be read at https://www.thecerbatgem.com/2017/08/30/cytokinetics-incorporated-cytk-given-average-recommendation-of-buy-by-analysts.html.

Shares of Cytokinetics, (NASDAQ:CYTK) traded up 2.599% on Wednesday, reaching $14.569. 286,214 shares of the company’s stock traded hands. The stock’s market capitalization is $781.86 million. Cytokinetics, has a 52 week low of $8.51 and a 52 week high of $17.20. The company has a 50 day moving average of $13.28 and a 200-day moving average of $13.17.

Cytokinetics, (NASDAQ:CYTK) last released its quarterly earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($0.60) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.57) by $0.03. Cytokinetics, had a negative net margin of 16.00% and a negative return on equity of 14.15%. The business had revenue of $3.05 million during the quarter, compared to the consensus estimate of $5.28 million. Equities research analysts forecast that Cytokinetics, will post ($2.46) earnings per share for the current year.

In other news, CEO Robert I. Blum sold 5,000 shares of the business’s stock in a transaction dated Tuesday, August 1st. The stock was sold at an average price of $13.79, for a total transaction of $68,950.00. Following the completion of the transaction, the chief executive officer now directly owns 84,785 shares in the company, valued at approximately $1,169,185.15. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Caryn Gordon Mcdowell sold 11,348 shares of the business’s stock in a transaction dated Tuesday, August 8th. The stock was sold at an average price of $12.47, for a total value of $141,509.56. Following the transaction, the insider now owns 21,570 shares of the company’s stock, valued at $268,977.90. The disclosure for this sale can be found here. Insiders have sold a total of 26,348 shares of company stock valued at $339,260 over the last 90 days. Corporate insiders own 7.20% of the company’s stock.

Several institutional investors have recently bought and sold shares of CYTK. Janus Henderson Group PLC bought a new position in Cytokinetics, during the second quarter valued at about $32,488,000. Vanguard Group Inc. raised its position in Cytokinetics, by 59.9% in the second quarter. Vanguard Group Inc. now owns 3,117,496 shares of the biopharmaceutical company’s stock valued at $37,721,000 after buying an additional 1,168,151 shares during the last quarter. State Street Corp raised its position in Cytokinetics, by 79.6% in the second quarter. State Street Corp now owns 1,674,335 shares of the biopharmaceutical company’s stock valued at $20,259,000 after buying an additional 741,909 shares during the last quarter. FMR LLC raised its position in Cytokinetics, by 8.8% in the first quarter. FMR LLC now owns 5,655,916 shares of the biopharmaceutical company’s stock valued at $72,679,000 after buying an additional 456,502 shares during the last quarter. Finally, Acadian Asset Management LLC raised its position in Cytokinetics, by 128.9% in the second quarter. Acadian Asset Management LLC now owns 766,263 shares of the biopharmaceutical company’s stock valued at $9,271,000 after buying an additional 431,457 shares during the last quarter. Institutional investors own 71.51% of the company’s stock.

About Cytokinetics,

Cytokinetics, Incorporated is a late-stage biopharmaceutical company. The Company is focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. It is focused on the discovery and development of small molecule therapeutics that modulate muscle function for the treatment of serious diseases and medical conditions.

Analyst Recommendations for Cytokinetics, (NASDAQ:CYTK)

Receive News & Stock Ratings for Cytokinetics Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytokinetics Incorporated and related stocks with our FREE daily email newsletter.